MX2023004942A - Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades. - Google Patents

Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.

Info

Publication number
MX2023004942A
MX2023004942A MX2023004942A MX2023004942A MX2023004942A MX 2023004942 A MX2023004942 A MX 2023004942A MX 2023004942 A MX2023004942 A MX 2023004942A MX 2023004942 A MX2023004942 A MX 2023004942A MX 2023004942 A MX2023004942 A MX 2023004942A
Authority
MX
Mexico
Prior art keywords
diseases
treatment
bicyclic compounds
compounds
compositions
Prior art date
Application number
MX2023004942A
Other languages
English (en)
Spanish (es)
Inventor
Robert Taylor
Douglas Boatman
Leen Kawas
Kevin Church
Jewel Johnston
Original Assignee
Athira Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athira Pharma Inc filed Critical Athira Pharma Inc
Publication of MX2023004942A publication Critical patent/MX2023004942A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2023004942A 2020-11-02 2021-11-01 Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades. MX2023004942A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063108660P 2020-11-02 2020-11-02
PCT/US2021/057563 WO2022094400A1 (en) 2020-11-02 2021-11-01 Bicyclic compounds and uses thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
MX2023004942A true MX2023004942A (es) 2023-07-06

Family

ID=81384389

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004942A MX2023004942A (es) 2020-11-02 2021-11-01 Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.

Country Status (12)

Country Link
US (1) US20240025903A1 (https=)
EP (1) EP4236944A4 (https=)
JP (1) JP2023550543A (https=)
KR (1) KR20230104191A (https=)
CN (2) CN119684295A (https=)
AR (1) AR124637A1 (https=)
AU (1) AU2021371026A1 (https=)
CA (1) CA3196582A1 (https=)
CL (2) CL2023001195A1 (https=)
IL (1) IL302465A (https=)
MX (1) MX2023004942A (https=)
WO (1) WO2022094400A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240121239A (ko) * 2021-12-17 2024-08-08 아티라 파마, 인코포레이티드 질환 치료를 위한 이환식 화합물의 용도
EP4518864A1 (en) * 2022-05-04 2025-03-12 Athira Pharma, Inc. Methods of treating neuropathies
JP2025515045A (ja) * 2022-05-04 2025-05-13 アティラ・ファーマ・インコーポレイテッド 神経炎症病態を治療する方法
EP4618996A1 (en) 2022-11-18 2025-09-24 Athira Pharma, Inc. Methods of treating inflammatory conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
AU2003284120A1 (en) * 2002-10-17 2004-05-04 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US7192976B2 (en) * 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
AU2005289560A1 (en) * 2004-09-28 2006-04-06 Angion Biomedica Corp. Small molecule modulators of cytokine activity
US7879898B1 (en) * 2006-02-14 2011-02-01 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
EP1947085A1 (en) * 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
CN102186853A (zh) * 2008-10-14 2011-09-14 株式会社棱镜生物实验室 治疗癌症α-螺旋模拟物
WO2014025832A1 (en) * 2012-08-06 2014-02-13 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
WO2017047762A1 (ja) * 2015-09-18 2017-03-23 国立大学法人鳥取大学 低分子化合物による癌と線維化の抑制と再生促進の効果

Also Published As

Publication number Publication date
EP4236944A4 (en) 2024-09-04
TW202233622A (zh) 2022-09-01
US20240025903A1 (en) 2024-01-25
WO2022094400A1 (en) 2022-05-05
EP4236944A1 (en) 2023-09-06
JP2023550543A (ja) 2023-12-01
CA3196582A1 (en) 2022-05-05
AR124637A1 (es) 2023-04-19
CN116568301A (zh) 2023-08-08
CL2023001195A1 (es) 2023-10-20
AU2021371026A9 (en) 2024-04-18
KR20230104191A (ko) 2023-07-07
IL302465A (en) 2023-06-01
CL2024000340A1 (es) 2024-08-16
CN119684295A (zh) 2025-03-25
AU2021371026A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
MX2023004942A (es) Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.
MX2024006123A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
MX2022010425A (es) Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
EP4620469A3 (en) Tricyclic urea compounds as jak2 v617f inhibitors
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
EP4438114A3 (en) Methods of making bempedoic acid and compositions of the same
PH12022553019A1 (en) Il-17a modulators
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MY140767A (en) Compounds, methods and compositions
MX2021011488A (es) Compuestos y usos de estos.
MX2025002953A (es) Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis
PH12022500021A1 (en) Il-17a modulators
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
MY140169A (en) Compounds, compositions, and methods
MX2025005941A (es) Moduladores de la actividad tnf-\03b1
MX2021007948A (es) Inhibidores de proteina de activacion de fibroblastos.
MX2022000712A (es) Moduladores de nlrp3.
MX2024011254A (es) Moduladores de nlrp3
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
MX2023008589A (es) Compuestos moduladores de gcn2 y usos de los mismos.
MX2025007184A (es) Triterpenoides sinteticos heteroaromaticos sustituidos polarmente en c17, y metodos de uso de los mismos
PH12022552447A1 (en) Nlrp3 modulators
WO2020154571A8 (en) Compounds and uses thereof
MY209530A (en) Methods and compositions for the treatment of hair loss